ondasdechoque.org
PT-BR

Greater trochanteric pain / gluteal tendinopathy · Randomized trial · 2023

How does shockwave compare with a steroid injection for outer hip pain?

In this trial of 60 people with outer hip pain, three sessions of radial shockwave, one a week, lowered pain from about 7 to about 1 out of 10 by three months. A single steroid injection gave a similar result, from about 7 to under 1.

Both helped
people with outer hip pain
60
sessions, one a week
3
months of follow-up
3

Good to know: There was no exercise programme during the study.

Çağlar Yağcı H, Yağcı İ, Bağcıer F Turkish Journal of Physical Medicine and Rehabilitation, 2023 · Read the paper ↗

What happened

Outer hip pain

0–10 pain scale · start and after three months

StartAfter 3 months

Pain fell from about 7 to about 1 out of 10 in both groups by three months: 1.0 with shockwave and 0.8 with the injection.
Show the numbers
GroupPeopleStartAfter 3 months
Radial shockwave326.841.03
Steroid injection286.960.78

The treatment

Radial shockwave

Radial, once a week for 3 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
3, one a week
Pulses
2,000 per session
Strength
2bar · 12 per second
Numbing
Not mentioned
Device
Modus
Everyone also got
Paracetamol allowed if needed; no exercise programme

Compared with: One steroid injection (40 mg triamcinolone with a local anaesthetic)

Settings are what each study used, not a prescription.

Who took part

60 adults aged 34 to 65 with outer hip pain (greater trochanteric pain syndrome) diagnosed by examination.

Side effects

Some people had short-lived pain after a session that usually settled within 24 hours; 12 people in the shockwave group took paracetamol. Nobody stopped shockwave early.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with clinically diagnosed GTPS (ages 34–65, although Methods screened patients aged 40–70). Of 96 patients screened, 64 were eligible; groups are reported as SWT n=32 and corticosteroid injection n=28 (60 in total). Four injection-group patients are then said to have been excluded (Methods: missed follow-up visits; Results: started NSAIDs for other diseases), yet Tables 1–2 keep n=28 and the completed sample is 60; the randomized, excluded and analyzed counts do not reconcile.

Radial ESWT32analyzed

Table 2 uses n=32 and n=28. Methods report 64 eligible patients assigned as 32 and 28 (60 in total), then four injection-group exclusions (missed follow-up in Methods; NSAID use in Results) while still reporting a completed sample of 60; the source does not reconcile these counts, so the randomized allocation is not recoverable.

Triamcinolone plus prilocaine injection28analyzed

Table 2 uses n=32 and n=28. Methods report 64 eligible patients assigned as 32 and 28 (60 in total), then four injection-group exclusions (missed follow-up in Methods; NSAID use in Results) while still reporting a completed sample of 60; the source does not reconcile these counts, so the randomized allocation is not recoverable.

Overall lateral hip pain2 reported outcomes
01
Baseline and month 3

Overall lateral hip pain

VAS, 0–10 cm cm

BaselineFollow-up
Radial ESWT
1.03
Triamcinolone plus prilocaine injection
0.78
010 cm
means
GroupnBaselineFollow-up
Radial ESWT326.84 (SD 0.95)1.03 (SD 1.03)
Triamcinolone plus prilocaine injection286.96 (SD 0.99)0.78 (SD 0.83)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.378

Radial ESWT versus corticosteroid injection: one between-group test from the repeated-measures model covering baseline, week 3 and month 3 (Table 2, **; F=0.789). Table 2 prints it in the week-3 row; it is not a test at a single visit.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test was not significant (p=0.378); both groups improved over time (p=0.001). This single test covers all three visits, so the same p value appears with the week-3 outcome; the source gives no between-group difference or confidence interval for any single visit.

Analysis details and source

The paper reports repeated-measures tests, not an adjusted mean difference or confidence interval. Nonsignificance does not establish equivalence. Table 2 prints the same shockwave means (6.84 → 1.03) for pain as for tenderness (the SDs differ); transcribed as printed.

02
Baseline and month 3

Greater-trochanter tenderness

VAS, 0–10 cm cm

BaselineFollow-up
Radial ESWT
1.03
Triamcinolone plus prilocaine injection
0.78
010 cm
means
GroupnBaselineFollow-up
Radial ESWT326.84 (SD 1.01)1.03 (SD 0.99)
Triamcinolone plus prilocaine injection287 (SD 1.05)0.78 (SD 0.73)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.185

Radial ESWT versus corticosteroid injection: one between-group test from the repeated-measures model covering baseline, week 3 and month 3 (Table 2, **; F=1.711). Table 2 prints it in the week-3 row; it is not a test at a single visit.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test was not significant (p=0.185); both groups improved over time (p=0.001). This single test covers all three visits, so the same p value appears with the week-3 outcome; the source gives no between-group difference or confidence interval for any single visit.

Analysis details and source

The paper reports repeated-measures tests, not an adjusted mean difference or confidence interval. Nonsignificance does not establish equivalence. The shockwave means (6.84 → 1.03) match the shockwave pain row (the SDs differ), and the injection week-3 and month-3 values are both 0.78 ± 0.73; transcribed as printed.

WOMAC total score1 reported outcome
03
Baseline and month 3

WOMAC total score

WOMAC 0–96; higher worse WOMAC points

BaselineFollow-up
Radial ESWT
6.73
Triamcinolone plus prilocaine injection
4.27
096 WOMAC points
means
GroupnBaselineFollow-up
Radial ESWT3247 (SD 8.8)6.73 (SD 6.54)
Triamcinolone plus prilocaine injection2846.78 (SD 9.56)4.27 (SD 4.35)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.287

Radial ESWT versus corticosteroid injection: one between-group test from the repeated-measures model covering baseline, week 3 and month 3 (Table 2, **; F=1.153). Table 2 prints it in the week-3 row; it is not a test at a single visit.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test was not significant (p=0.287); both groups improved over time (p=0.001). This single test covers all three visits, so the same p value appears with the week-3 outcome; the source gives no between-group difference or confidence interval for any single visit.

Analysis details and source

The paper reports repeated-measures tests, not an adjusted mean difference or confidence interval. Nonsignificance does not establish equivalence.

VAS pain at week 31 reported outcome
04
Week 3

VAS pain at week 3

Visual Analog Scale (VAS) centimeters

means
GroupnBaselineFollow-up
Radial ESWT32—1.09 (SD 0.96)
Triamcinolone plus prilocaine injection28—0.78 (SD 0.73)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.378

Radial ESWT versus corticosteroid injection: one between-group test from the repeated-measures model covering baseline, week 3 and month 3 (Table 2, **; F=0.789). Table 2 prints it in the week-3 row; it is not a test at a single visit.

General linear model for repeated measures: between-group effect (Table 2, **)

Week-3 means from Table 2. The between-group p value (0.378, F=0.789) is the same single repeated-measures test reported with the baseline-to-month-3 pain outcome, not a separate week-3 comparison; both groups improved over time (p=0.001).

Analysis details and source

Table 2 lists F=0.789 and p=0.378 for the between-group test (**), and p=0.001 for change over time (*). Do not mistake the F statistic 0.789 for the between-group p value. The injection value 0.78 ± 0.73 also appears in the injection tenderness rows at week 3 and month 3; transcribed as printed.

Greater trochanter tenderness at week 31 reported outcome
05
Week 3

Greater trochanter tenderness at week 3

Trochanteric tenderness VAS centimeters

means
GroupnBaselineFollow-up
Radial ESWT32—1.18 (SD 1.06)
Triamcinolone plus prilocaine injection28—0.78 (SD 0.73)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.185

Radial ESWT versus corticosteroid injection: one between-group test from the repeated-measures model covering baseline, week 3 and month 3 (Table 2, **; F=1.711). Table 2 prints it in the week-3 row; it is not a test at a single visit.

General linear model for repeated measures: between-group effect (Table 2, **)

Week-3 means from Table 2. The between-group p value (0.185, F=1.711) is the same single repeated-measures test reported with the baseline-to-month-3 tenderness outcome, not a separate week-3 comparison; both groups improved over time (p=0.001).

Analysis details and source

Table 2 footnote marks the within-time test with * (p=0.001) and the between-group test with ** (p=0.185); do not conflate them. Values are means±SD. The injection value is identical at week 3 and month 3 (0.78 ± 0.73); transcribed as printed.

WOMAC at week 31 reported outcome
06
Week 3

WOMAC at week 3

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score points

means
GroupnBaselineFollow-up
Radial ESWT32—7.59 (SD 7.59)
Triamcinolone plus prilocaine injection28—5.1 (SD 3.83)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.287

Radial ESWT versus corticosteroid injection: one between-group test from the repeated-measures model covering baseline, week 3 and month 3 (Table 2, **; F=1.153). Table 2 prints it in the week-3 row; it is not a test at a single visit.

General linear model for repeated measures: between-group effect (Table 2, **)

Week-3 means from Table 2. The between-group p value (0.287, F=1.153) is the same single repeated-measures test reported with the baseline-to-month-3 WOMAC outcome, not a separate week-3 comparison; both groups improved over time (p=0.001).

Analysis details and source

Table 2 footnote marks the within-time test with * (p=0.001) and the between-group test with ** (p=0.287); do not conflate them. Values are means±SD. The shockwave SD equals its mean (7.59 ± 7.59); transcribed as printed.

Emotional role limitation1 reported outcome
07
Baseline and month 3

Emotional role limitation

SF-36 emotional role limitation SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3258.5 (SD 19.67)59.21 (SD 18.6)
Triamcinolone plus prilocaine injection2859.22 (SD 19.83)60.92 (SD 18.24)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.805

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.805). Table 2 reports p=0.069 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.069 with * and between-group p=0.805 with **.

Energy/vitality1 reported outcome
08
Baseline and month 3

Energy/vitality

SF-36 energy SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3259.06 (SD 15.78)61.25 (SD 13.55)
Triamcinolone plus prilocaine injection2854.82 (SD 12.58)57.32 (SD 10.49)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.859

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.859). Table 2 reports p=0.226 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.226 with * and between-group p=0.859 with **.

Mental health1 reported outcome
09
Baseline and month 3

Mental health

SF-36 mental health SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3263.84 (SD 13.72)63.96 (SD 14.18)
Triamcinolone plus prilocaine injection2864.28 (SD 11.77)64.35 (SD 11.93)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.902

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.902). Table 2 reports p=0.687 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.687 with * and between-group p=0.902 with **.

Social function1 reported outcome
10
Baseline and month 3

Social function

SF-36 social function SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3253.64 (SD 15.8)59.89 (SD 13.09)
Triamcinolone plus prilocaine injection2856.62 (SD 12.64)60.91 (SD 10.24)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.546

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.546). Table 2 reports p=0.279 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.279 with * and between-group p=0.546 with **.

General health1 reported outcome
11
Baseline and month 3

General health

SF-36 general health SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3255.93 (SD 15.26)56.28 (SD 14.76)
Triamcinolone plus prilocaine injection2856.07 (SD 13.28)56.03 (SD 12.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.287

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.287). Table 2 reports p=0.783 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.783 with * and between-group p=0.287 with **.

Physical functioning1 reported outcome
12
Baseline and month 3

Physical functioning

SF-36 physical functioning SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3258.9 (SD 13.42)70.9 (SD 13.42)
Triamcinolone plus prilocaine injection2858.75 (SD 11.98)70.75 (SD 11.98)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.962

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.962). Table 2 reports p=0.001 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.001 with * and between-group p=0.962 with **. Each group's SD is identical before and after treatment (13.42; 11.98); transcribed as printed.

Role limitations due to physical health1 reported outcome
13
Baseline and month 3

Role limitations due to physical health

SF-36 role limitations due to physical health SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3236.71 (SD 16.78)43.81 (SD 16.9)
Triamcinolone plus prilocaine injection2836.6 (SD 14.4)45.42 (SD 14.67)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.853

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.853). Table 2 reports p=0.001 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.001 with * and between-group p=0.853 with **.

Bodily pain1 reported outcome
14
Baseline and month 3

Bodily pain

SF-36 bodily pain SF-36 score points

means
GroupnBaselineFollow-up
Radial ESWT3246.18 (SD 11.06)53.34 (SD 10.77)
Triamcinolone plus prilocaine injection2845.75 (SD 12.4)49.64 (SD 9.4)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.432

Radial ESWT versus corticosteroid injection: between-group test from the repeated-measures model covering baseline and month 3 (Table 2, **), printed in the month-3 row.

General linear model for repeated measures: between-group effect (Table 2, **)

The repeated-measures between-group test across baseline and month 3 was not statistically significant (p=0.432). Table 2 reports p=0.001 for change over time (*).

Analysis details and source

Baseline and month-3 means±SD are transcribed by group. Table 2 marks within-time p=0.001 with * and between-group p=0.432 with **.

How treatment was delivered
Device and modality

Radial extracorporeal shockwave therapy using Modus device

Dose

2,000 beats, 20-mm applicator, 12 Hz, 2 bar

Schedule and target

One session weekly for three weeks, greater trochanter region, lateral decubitus

Comparator protocol

One injection: 40 mg triamcinolone acetonide plus 2 mL 2% prilocaine

Co-care

Paracetamol 1,000 mg/day permitted; no exercise program during study

HARMS & TOLERABILITY

Twelve ESWT participants used paracetamol; transient post-procedure pain generally resolved within 24 hours. No ESWT discontinuations. Four injection participants were excluded after starting NSAIDs for other illnesses; this is not described as an injection adverse event.

LIMITS OF THE ANALYSIS

Only three months of follow-up; long-term efficacy and recurrence are unknown.

Four injection-group participants were reported excluded after randomization, with different reasons in Methods (missed follow-up visits) and Results (NSAID use), yet the reported group sizes of 32 and 28 and the 64 eligible patients do not add up; the randomized denominators are not reported consistently, and no intention-to-treat analysis is reported.

No imaging confirmation separated tendinopathy from bursitis; no confidence intervals for between-group comparisons were reported.

Several Table 2 cells repeat exactly: shockwave pain and tenderness have the same means (6.84 → 1.03); the injection value 0.78 ± 0.73 appears for tenderness at week 3 and month 3 and for pain at week 3; shockwave WOMAC at week 3 is 7.59 ± 7.59; SF-36 physical-function SDs are identical before and after treatment, and both groups rise by exactly 12.00 points; and the SF-36 general-health between-group F and p (1.153; 0.287) repeat WOMAC's. They are transcribed as printed; the pattern suggests possible copying errors in the published table.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Only three months of follow-up; long-term efficacy and recurrence are unknown.
  • Four injection-group participants were reported excluded after randomization, with different reasons in Methods (missed follow-up visits) and Results (NSAID use), yet the reported group sizes of 32 and 28 and the 64 eligible patients do not add up; the randomized denominators are not reported consistently, and no intention-to-treat analysis is reported.
  • No imaging confirmation separated tendinopathy from bursitis; no confidence intervals for between-group comparisons were reported.
  • Several Table 2 cells repeat exactly: shockwave pain and tenderness have the same means (6.84 → 1.03); the injection value 0.78 ± 0.73 appears for tenderness at week 3 and month 3 and for pain at week 3; shockwave WOMAC at week 3 is 7.59 ± 7.59; SF-36 physical-function SDs are identical before and after treatment, and both groups rise by exactly 12.00 points; and the SF-36 general-health between-group F and p (1.153; 0.287) repeat WOMAC's. They are transcribed as printed; the pattern suggests possible copying errors in the published table.
Research review

Source-linked critical reading

Randomized comparative clinical trial

Reading depthMaterial consulted
Technical source record

Complete article XML read, including Methods, Results, Tables 1–2, Discussion, Conclusion and disclosures.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Single-center, single-blind randomized active-comparator study. Sixty participants completed follow-up: 32 in ESWT and 28 in injection; four injection participants were excluded after starting NSAIDs. Initial randomized denominators are not explicitly stated in the reported results.

Participants

Adults aged 40–70 with at least six weeks of lateral hip pain and clinical provocation/tenderness criteria. Imaging was not used to distinguish bursal from tendon pathology.

Intervention

Radial Modus device; lateral decubitus; 2,000 beats using a 20-mm applicator, 12 Hz, 2 bar, once weekly for three weeks. Paracetamol 1,000 mg/day was permitted.

Comparator

Single injection of 40 mg triamcinolone acetonide plus 2 mL of 2% prilocaine at the most tender point. No exercise program was provided during the study.

Outcomes

Pain, trochanteric tenderness and WOMAC were assessed at baseline, week 3 and month 3, and SF-36 at baseline and month 3. Primary outcomes improved within both groups; ESWT arm mean pain was 6.84 cm at baseline and 1.03 at month 3; injection was 6.96 and 0.78.

Between-group interpretation

The reported between-group tests were nonsignificant for VAS (p=.378), tenderness (p=.185), WOMAC (p=.287), and SF-36 subscales (all p>.05). These tests do not establish equivalence or noninferiority.

Harms

Twelve ESWT participants reported paracetamol use; treatment-related pain generally resolved within 24 hours and was tolerated. Four injection participants were excluded after using NSAIDs for other conditions. No patient discontinued ESWT.

Limitations

Follow-up ended at three months; four injection participants were excluded, and imaging confirmation was absent. The study did not report between-group effect estimates with confidence intervals.

Applicability

This trial informs a short-term choice between one injection and a three-session radial protocol for clinically diagnosed GTPS. It does not show that either treatment is better than no treatment, nor that they are interchangeable.

What a stronger study should do

A larger registered trial should retain randomized participants, use intention-to-treat analysis, prespecify a clinically justified noninferiority/equivalence margin if intended, report confidence intervals and track recurrence, medication use and adverse events beyond three months.

THE ORIGINAL SOURCE

Read the original article.

Comparison of shock wave therapy and corticosteroid injection in the treatment of greater trochanteric pain syndrome: A single-blind, randomized study.

Çağlar Yağcı H, Yağcı İ, Bağcıer F. · Turkish journal of physical medicine and rehabilitation · 2023

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →